Skip to content

US · VTVT · BIOTECHNOLOGY

vTv Therapeutics Inc. (VTVT) intrinsic value and stock valuation

$15.51as of 2026-11-21 · Mkt cap 90.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

vTv Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values VTVT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VTVT’s statements →

vTv Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology High Point, NC 27265 vtvtherapeutics.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-26.97M
20132025
Free cash flow
-$-25.25M
20132025
Total equity
$64.4M+76.2% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$1.02M$0.00$2.02M$4M
Operating income-$-32.81M-$-24.18M-$-25.5M-$-22.54M-$-21.66M
Net income-$-26.97M-$-18.46M-$-20.25M-$-19.16M-$-12.99M
EPSd-$-3.2M-$-3.2M-$-9.74M-$-9.98M-$-8.27M
Operating cash flow-$-25.25M-$-25.31M-$-19.08M-$-15.25M-$-19.31M
Capital expenditure$0.00$0.00$0.00-$-20K$0.00
Free cash flow-$-25.25M-$-25.31M-$-19.08M-$-15.27M-$-19.31M
Total assets$89.9M$38.3M$11M$33.2M$25.5M
Total debt$0.00$170K$530K$720K$930K
Net debt-$-88.93M-$-36.58M-$-8.92M-$-11.41M-$-12.48M
Total equity$64.4M$14.3M-$-18.55M$5.84M$15.2M
Cash and short-term investments$88.9M$36.8M$9.45M$12.1M$13.4M
Income statement
20252024202320222021
Revenue$0.00$1.02M$0.00$2.02M$4M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$1.02M$0.00$2.02M$4M
Research and development expenses$17.9M$11.6M$13.6M$12.4M$13.3M
Selling, general and administrative expenses$15M$13.7M$11.9M$12.2M$12.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$32.8M$25.2M$25.5M$24.6M$25.7M
Cost and expenses$32.8M$25.2M$25.5M$24.6M$25.7M
Interest income$1.87M$1.56M$470K$350K$0.00
Interest expense$10K$0.00$10K$10K$10K
Depreciation and amortization$20K$90K$90K$90K$90K
Ebitda-$-31.06M-$-22.52M-$-25.86M-$-24.77M-$-17.52M
Operating income-$-32.81M-$-24.18M-$-25.5M-$-22.54M-$-21.66M
Total other income/expenses, net$1.73M$1.57M-$-460K-$-2.33M$4.05M
Income before tax-$-31.08M-$-22.61M-$-25.97M-$-24.87M-$-17.62M
Income tax expense$0.00$100K$0.00$200K$120K
Net income-$-26.97M-$-18.46M-$-20.25M-$-19.16M-$-12.99M
Weighted average shares outstanding$8.42M$5.77M$2.08M$1.92M$1.57M
Weighted average diluted shares outstanding$8.42M$5.77M$2.08M$1.92M$1.57M
Balance sheet
20252024202320222021
Cash and short-term investments$88.9M$36.8M$9.45M$12.1M$13.4M
Net receivables$0.00$60K$100K$12.4M$60K
Inventory$0.00$0.00$0.00$0.00$100K
Total current assets$89.9M$38.1M$10.7M$27.1M$15.6M
Property, plant and equipment, net$0.00$150K$360K$560K$680K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$5.59M$9.17M
Total non-current assets$10K$150K$360K$6.14M$9.85M
Total assets$89.9M$38.3M$11M$33.2M$25.5M
Accounts payable$1.13M$940K$4.08M$2.46M$1.88M
Short-term debt$0.00$170K$360K$380K$440K
Deferred revenue$0.00$0.00$20K$20K$40K
Total current liabilities$6.64M$5.2M$10.6M$7.71M$8.5M
Long-term debt$0.00$0.00$170K$340K$490K
Deferred revenue, non-current$18.7M$18.7M$18.7M$18.7M$0.00
Total non-current liabilities$18.8M$18.8M$19M$19.7M$1.75M
Capital lease obligations$0.00$170K$340K$490K$680K
Total liabilities$25.5M$24M$29.6M$27.4M$10.3M
Common stock$40K$30K$30K$30K$900K
Retained earnings-$-326.69M-$-299.72M-$-281.04M-$-265.52M-$-248.83M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$64.4M$14.3M-$-18.55M$5.84M$15.2M
Total investments$0.00$0.00$0.00$5.59M$9.17M
Total debt$0.00$170K$530K$720K$930K
Net debt-$-88.93M-$-36.58M-$-8.92M-$-11.41M-$-12.48M
Cash flow statement
20252024202320222021
Net income-$-31.08M-$-22.7M-$-20.25M-$-19.16M-$-17.73M
Depreciation and amortization$20K$90K$90K$90K$90K
Stock-based compensation$3.77M$2.76M$1.58M$0.00$2.36M
Change in working capital$1.89M-$-5.44M$4.39M$5.38M$40K
Accounts receivable$0.00$40K$70K-$-120K$100K
Inventory$0.00$0.00$0.00$0.00-$-890K
Accounts payable$1.53M$0.00$2.93M-$-860K$1.83M
Net cash provided by operating activities-$-25.25M-$-25.31M-$-19.08M-$-15.25M-$-19.31M
Investments in property, plant and equipment$0.00$0.00$0.00-$-20K$0.00
Acquisitions, net$0.00$0.00$4.4M$0.00$0.00
Net cash used for investing activities$0.00$0.00$4.4M-$-20K$0.00
Common stock issued$77.5M$52.8M$12M$14.8M$26.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$77.4M$52.6M$12M$14M$27M
Net change in cash$52.2M$27.3M-$-2.68M-$-1.29M$7.67M
Cash at end of period$88.9M$36.8M$9.45M$12.1M$13.4M
Operating cash flow-$-25.25M-$-25.31M-$-19.08M-$-15.25M-$-19.31M
Capital expenditure$0.00$0.00$0.00-$-20K$0.00
Free cash flow-$-25.25M-$-25.31M-$-19.08M-$-15.27M-$-19.31M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About vTv Therapeutics Inc.

        vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

        CEO
        Paul J. Sekhri
        Employees
        26
        Beta
        0.29

        Explore

        Frequently asked questions

        What is the intrinsic value of vTv Therapeutics Inc. (VTVT)?

        InvestorsCraft does not currently publish an intrinsic value for VTVT. How the IC value is calculated.

        Is VTVT undervalued?

        InvestorsCraft does not publish an undervaluation signal for VTVT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.